Indeed, DSIP and its alternative preparation Deltaran significantly increase blood supply during CNS stress such as chemotherapy or even ischemia
This drug candidate is a long-acting peptide designed to target three different receptors associated with weight loss, offering a potential new avenue for tackling obesity
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
In January 2023, Versanis launched a phase 2b human trial of bimagrumab as an obesity treatment, either alone or co-administered with semaglutide, Novo Nordisks GLP-1 agonist
Crackers, chips, popcorn, cereal, and granola can seem harmless, but they often crowd out protein and are easy to overeat before fullness catches up
References Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE